136 related articles for article (PubMed ID: 9005546)
1. Financial interests constrain drug development.
Garattini S
Science; 1997 Jan; 275(5298):287. PubMed ID: 9005546
[No Abstract] [Full Text] [Related]
2. Surviving the blockbuster syndrome.
Service RF
Science; 2004 Mar; 303(5665):1796-9. PubMed ID: 15031490
[No Abstract] [Full Text] [Related]
3. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
[TBL] [Abstract][Full Text] [Related]
4. Cutting the cost of drug development?
Rawlins MD
Nat Rev Drug Discov; 2004 Apr; 3(4):360-4. PubMed ID: 15060531
[No Abstract] [Full Text] [Related]
5. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
Federsel HJ
Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
[TBL] [Abstract][Full Text] [Related]
6. [Discount for only one drug of the same group leads to impaired health care quality].
Bergström R
Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044
[No Abstract] [Full Text] [Related]
7. The brains behind blockbusters.
Couzin J
Science; 2005 Jul; 309(5735):728. PubMed ID: 16051786
[No Abstract] [Full Text] [Related]
8. When Pharma merges, R&D is the dowry.
Agnew B
Science; 2000 Mar; 287(5460):1952-3. PubMed ID: 10755948
[No Abstract] [Full Text] [Related]
9. The pharmaceutical industry--to whom is it accountable?
Hayes TA
N Engl J Med; 2000 Nov; 343(19):1416; discussion 1417. PubMed ID: 11183881
[No Abstract] [Full Text] [Related]
10. Measure for measure.
Dughan L
Biotechnology (N Y); 1995 Sep; 13(9):949-53. PubMed ID: 9678952
[No Abstract] [Full Text] [Related]
11. Drug discovery.
Kennedy D
Science; 2004 Mar; 303(5665):1729. PubMed ID: 15031461
[No Abstract] [Full Text] [Related]
12. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.
Garrison LP; Mansley EC; Abbott TA; Bresnahan BW; Hay JW; Smeeding J
Value Health; 2010; 13(1):8-13. PubMed ID: 19883405
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic treatments for dry eye: a worthwhile investment?
Novack GD
Cornea; 2002 Jan; 21(1):4-5. PubMed ID: 11805498
[TBL] [Abstract][Full Text] [Related]
14. Should Third-World countries pay the tab for new drug development?
Gurwitz D
Acad Med; 1999 Mar; 74(3):203. PubMed ID: 10099632
[No Abstract] [Full Text] [Related]
15. Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry.
DiMasi JA; Hansen RW; Grabowski HG; Lasagna L
Pharmacoeconomics; 1995 Feb; 7(2):152-69. PubMed ID: 10155302
[TBL] [Abstract][Full Text] [Related]
16. Key factors in the rising cost of new drug discovery and development.
Dickson M; Gagnon JP
Nat Rev Drug Discov; 2004 May; 3(5):417-29. PubMed ID: 15136789
[No Abstract] [Full Text] [Related]
17. The pharmaceutical industry--to whom is it accountable?
Holmer AF
N Engl J Med; 2000 Nov; 343(19):1415; discussion 1417. PubMed ID: 11183877
[No Abstract] [Full Text] [Related]
18. Will lower drug prices jeopardize drug research? A policy fact sheet.
Light DW; Lexchin J
Am J Bioeth; 2004; 4(1):W1-4. PubMed ID: 15035915
[No Abstract] [Full Text] [Related]
19. The global drug gap.
Reich MR
Science; 2000 Mar; 287(5460):1979-81. PubMed ID: 10755953
[TBL] [Abstract][Full Text] [Related]
20. Attrition and translation.
Duyk G
Science; 2003 Oct; 302(5645):603-5. PubMed ID: 14576424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
